0001387131-21-006822.txt : 20210623
0001387131-21-006822.hdr.sgml : 20210623
20210623181459
ACCESSION NUMBER: 0001387131-21-006822
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210621
FILED AS OF DATE: 20210623
DATE AS OF CHANGE: 20210623
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC
CENTRAL INDEX KEY: 0001131399
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: X0
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40502
FILM NUMBER: 211039711
BUSINESS ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
BUSINESS PHONE: 011442080475000
MAIL ADDRESS:
STREET 1: 980 GREAT WEST ROAD
CITY: BRENTFORD MIDDLESEX
STATE: X0
ZIP: TW8 9GS
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lyell Immunopharma, Inc.
CENTRAL INDEX KEY: 0001806952
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 833006753
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 EAST JAMIE COURT
STREET 2: SUITE 301
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650 695-0677
MAIL ADDRESS:
STREET 1: 400 EAST JAMIE COURT
STREET 2: SUITE 301
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
gsk-form4_062121.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2021-06-21
0
0001806952
Lyell Immunopharma, Inc.
LYEL
0001131399
GLAXOSMITHKLINE PLC
980 GREAT WEST ROAD
BRENTFORD MIDDLESEX
X0
TW8 9GS
UNITED KINGDOM
0
0
1
0
Common Stock
2021-06-21
4
C
0
30253189
A
30253189
I
See Footnote
Series AA Preferred Stock
2021-06-21
4
C
0
30253189
D
Common Stock
30253189
0
I
See Footnote
The Series AA Preferred Stock automatically converted into common stock on a 1-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The shares reported herein are held of record by Glaxo Group Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
/s/ Victoria A. Whyte
2021-06-23